Meet ImmuneCyte

ImmuneCyte Inc. is a global, clinical-stage biopharmaceutical company engaged in the research and development of innovative cell and gene therapeutics, including chimeric antigen receptor (CAR)-T cell, CAR-NK cell, and mononuclear cell therapies, for the treatment of cancer, vascular, orthopedic and aging-related diseases. We are a privately held company with headquarter in Irvine, California and access to 30,000 sq. ft. of GMP-qualified laboratory and office facilities in Tianjin, China. The location of our operations provides us with many potential strategic advantages, including proximity to world’s largest pharmaceutical market and access to largest number of patients.

We build our immuno-oncology pipeline based on our proprietary CARTXpress™ platform, licensed from one of our parent companies, ThermoGenesis Holdings Inc. The technology platforms were developed in the U.S. by a dedicated professional team of biologists, engineers and other clinical professionals. We leverage this high-efficient and versatile cellular processing and manufacturing platform to develop a robust pipeline of cell and gene therapy products for the treatment of cancers and rare genetic disorders. Currently, we are in clinical stage of developing several unique chimeric antigen receptor (CAR) T cell and natural killer cell-based therapeutics for advanced hematopoietic cancers and solid tumors. We have also used this platform to develop advanced cell-based gene therapies for the treatment of severe cases of b-thalassemia, a devastating blood genetic disorder that affects more than 60,000 infants each year.